UniDock-Pro improves early enrichment in drug discovery by 2.42-fold, indicating a robust high-throughput virtual screening solution.
The screening of ultralarge chemical libraries requires high-throughput computational tools that can efficiently exploit all available structural and chemical information. We present UniDock-Pro, a unified platform based on the GPU-accelerated Uni-Dock architecture that integrates structure-based virtual screening (SBVS), ligand-based virtual screening (LBVS), and a novel hybrid virtual screening mode. By capitalizing on inter-ligand (batch) parallelism, UniDock-Pro achieves substantial throughput gains, enabling the processing of millions of compounds per day on a single GPU. We significantly enhanced the LBVS methodology by implementing a smooth, Lennard-Jones-like potential optimized for gradient-based search, which replaces the rugged recursive model employed in our previous work. This optimization yields a substantial 2.42-fold improvement in early enrichment (EF1%) over the legacy AutoDock-SS on the DUDE-Z benchmark. The Hybrid mode combines complementary information by integrating receptor- and ligand-derived grid maps on-the-fly during the conformational search, delivering strong early enrichment on DUDE-Z and competitive performance on the more stringent VSDS-vd TrueDecoy benchmark. To understand the mechanisms underlying this synergy, we introduce Force Field Complementarity Analysis (FFCA), a method for quantifying the spatial alignment between receptor and ligand force fields. UniDock-Pro offers a robust, versatile, and highly efficient solution for accelerating drug discovery campaigns across the expansive modern chemical space.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: